Lexicon Pharma's diabetes drug successful in mid-stage study

April 14 Mon Apr 14, 2014 6:15am EDT

April 14 (Reuters) - Lexicon Pharmaceuticals Inc said its experimental drug to treat diabetes met the main goal of reducing the use of insulin at meal times in a mid-stage study on patients with type 1 diabetes.

The company's shares rose about 19 percent to $1.89 in trading before the bell.

Lexicon said the drug, codenamed LX4211, reduced the total dose of insulin taken by patients at meal times by 32 percent, compared with a 6 percent reduction in patients given a placebo. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.